Immunotherapy of type-1 allergies with virus-like particles and CpG-motifs

Immunotherapy of Allergic Rhinitis: New Therapeutic Opportunities with Virus-like Particles Filled with Cpg Motifs

(2013) Ludger Klimek et al.   American Journal of Rhinology & Allergy

Novel birch pollen specific immunotherapy formulation based on contiguous overlapping peptides

(2013) Céline Pellaton et al.   Clinical and Translational Allergy

Subcutaneous and Sublingual Immunotherapy for Allergic Rhinitis: What is the Evidence?

(2012) Sarah K. Wise et al.   American Journal of Rhinology & Allergy

The hygiene hypothesis in allergy and asthma

(2012) Collin Brooks et al.   Current Opinion in Allergy and Clinical Immunology

Fel d 1–derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: A randomized, placebo-controlled study

(2012) Deepen Patel et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Epicutaneous allergen administration: is this the future of allergen-specific immunotherapy?

(2011) G. Senti et al.   ALLERGY

Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study

(2011) L. Klimek et al.   CLINICAL AND EXPERIMENTAL ALLERGY

CpG DNA as a vaccine adjuvant

(2011) Christian Bode et al.   Expert Review of Vaccines

Mechanisms of allergen-specific immunotherapy

(2011) Cezmi A. Akdis et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Allergic rhinitis: Direct and indirect costs

(2010) Michael S. Blaiss   ALLERGY AND ASTHMA PROCEEDINGS

Efficacy and Safety of a Glutaraldehyde-Modified House Dust Mite Extract in Allergic Rhinitis

(2010) Herbert Riechelmann et al.   American Journal of Rhinology & Allergy

Designing CD8+ T cell vaccines: it's not rocket science (yet)

(2010) Jonathan W Yewdell   CURRENT OPINION IN IMMUNOLOGY

TLR1/2, TLR7, and TLR9 Signals Directly Activate Human Peripheral Blood Naive and Memory B Cell Subsets to Produce Cytokines, Chemokines, and Hematopoietic Growth Factors

(2010) Sudhanshu Agrawal et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Cutting Edge: Type I IFN Reverses Human Th2 Commitment and Stability by Suppressing GATA3

(2010) J. P. Huber et al.   JOURNAL OF IMMUNOLOGY

Memory and Effector CD8 T-cell Responses After Nanoparticle Vaccination of Melanoma Patients

(2010) Daniel E. Speiser et al.   JOURNAL OF IMMUNOTHERAPY

Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists

(2009) Jörg Vollmer et al.   ADVANCED DRUG DELIVERY REVIEWS

Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial

(2009) G. Senti et al.   CLINICAL AND EXPERIMENTAL ALLERGY

TLR Cross-Talk Specifically Regulates Cytokine Production by B Cells from Chronic Inflammatory Disease Patients

(2009) M. Jagannathan et al.   JOURNAL OF IMMUNOLOGY

Viral Sequestration of Antigen Subverts Cross Presentation to CD8+ T Cells

(2009) Eric F. Tewalt et al.   PLoS Pathogens

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

(2008) J. Bousquet et al.   ALLERGY

The coming of age of virus-like particle vaccines

(2008) Gary T. Jennings et al.   BIOLOGICAL CHEMISTRY

Nanoparticles target distinct dendritic cell populations according to their size

(2008) Vania Manolova et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Phase 1 Evaluation of Intralesionally Injected TLR9-agonist PF-3512676 in Patients With Basal Cell Carcinoma or Metastatic Melanoma

(2008) Maja A. Hofmann et al.   JOURNAL OF IMMUNOTHERAPY

Allergen-related approaches to immunotherapy

(2008) Jennifer M. Rolland et al.   PHARMACOLOGY & THERAPEUTICS

Intralymphatic allergen administration renders specific immunotherapy faster and safer: A randomized controlled trial

(2008) G. Senti et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA